Quietmind Foundation

  • Home
  • Services
    • Photobiomodulation (Light Therapy)
    • Neurofeedback
  • About
  • Clinical Trials
    • Light Therapy for Dementia
    • Vielight Clinical Trial
  • Research
  • Equipment
  • Blog

Leading Edge Commentary

Novel Biomarker (Aβ42) found for Alzheimer's Disease

1/25/2022

0 Comments

 
This report involves the recognition of Aβ42, a protein that function as as a neurotoxin and now attributed to the development of Alzheimer's disease 

Key Takeaways
  • Measurement of the rate of cellular amyloid uptake and metabolic production of toxic amyloid species could be used as novel biomarkers for early and/or differential diagnosis of Alzheimer's disease (AD).
  • Estimated beta-amyloid (Aβ42) cellular uptake can be more than two times greater in AD patients compared to cognitively normal subjects. A less pronounced yet increased uptake rate was also observed in patients with late-onset mild cognitive impairment (MCI).
  • This increased uptake may prove to be a key mechanism defining age-related AD progression.
  • ​The increased cellular amyloid uptake in AD and LMCI may lead to quicker disease progression, but early-onset MCI may result from increased production of toxic amyloid metabolites.​
Of particular relevance is that the Aβ42 protein was shown to be significantly reduced in animal trials involving 1072nm photobiomodulation by researchers at Durham University. (Grillo, 2013) showed that this particular protein along with several others were reduce in the animals that showed improved cognitive and behavioral functioning after a trial of light stimulation. This is the same wavelength of light being used in the Neuradiant 1070 4Q transcranial photobiomodulation technology available now through Neuronic Devices Ltd. (neuronic.online) 


(Grillo SL, Duggett NA, Ennaceur A, Chazot PL (2013). Non-invasive infra-red therapy (1072nm) reduces β-amyloid protein levels in the brain of an Alzheimer’s disease mouse model, TASTPM. J Photochem Photobiology B Biology, 123:13–22.)

Full article here: www.medscape.com/viewarticle/

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    QMF News

    Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general. 

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    August 2022
    July 2022
    June 2022
    April 2022
    March 2022
    February 2022
    January 2022
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    October 2019
    September 2019
    August 2019
    June 2019
    May 2019
    April 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    April 2018
    March 2018
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    May 2017

    Categories

    All
    Alzheimer's
    Biofeedback
    Breathing Training
    Dementia
    Dementia Treatment
    Drug Free Anxiety Treatment
    Infrared Light
    Light Therapy
    Neurofeedback
    Neurotherapy
    Panic Disorder
    Photobiomodulation
    Relaxation
    TBI Treatment
    Therapy

    RSS Feed

Powered by Create your own unique website with customizable templates.
  • Home
  • Services
    • Photobiomodulation (Light Therapy)
    • Neurofeedback
  • About
  • Clinical Trials
    • Light Therapy for Dementia
    • Vielight Clinical Trial
  • Research
  • Equipment
  • Blog